louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05511090: Prospective Study to Observe and Manage Progression of Pulmonary Nodules
Official title: Diagnosis and Management of Incidental Pulmonary Nodules: a Prospective Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Lung Nodules
Lead sponsor: Chinese Chronic Respiratory Disease Research Network
Sponsor class: NETWORK
First posted: 2022-08-22
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: LNs patients aged 18 years and older who were previously treated in Guang'anmen hospital.

Brief summary: Based on the previous review and research, we would like to further observe the nodule changes in patients with pulmonary nodules. These changes include factors such as the reason for the further enlargement or deterioration of the nodule, time, lifestyle, the patient's region, and hereditary medical history. At the same time, we will further look at the corresponding characteristics of a population that does not change the size and nature of the nodule, including age, gender, and all the factors discussed above. On this basis, we can propose more scientific methods for the treatment and management of pulmonary nodules, and provide a more reliable clinical reference for the clinical treatment of pulmonary nodules.


Eligibility criteria: Inclusion Criteria:

LNs patients aged 18 years and older who were previously treated in Guang'anmen hospital.

Exclusion Criteria:

(1) had the LNs removed; (2) LNs less than or equal to 3 mm in size; (3) had not undergone thorax CT; (4) had failed to complete treatment; (5) had incomplete medical records or was lost to follow-up.

Primary outcomes:
measure: Changes in nodule size by CT scan in patients with pulmonary nodules during follow-up.
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02552290: Immediate Effects Cervicothoracic Manipulation Versus Passive Upper Trapezius Stretch
Official title: Effects of Cervicothoracic Manipulation and Passive Stretching to the Upper Trapezius Muscle on Pressure Pain Thresholds and Cervical Range of Motion on Healthy Individuals
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Neck Pain
Lead sponsor: University of Nevada, Las Vegas
Sponsor class: OTHER
First posted: 2015-09-17
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The proposed project seeks to evaluate the influence of cervicothoracic (CT) manipulation and passive stretching to the upper trapezius on pressure pain thresholds and range of motion (ROM) in individuals without recent complain of neck pain.

Detailed description: Not needed

Eligibility criteria: Inclusion Criteria:

1. No current history or past history of neck pain; able to lie on back or stomach without difficulty

Exclusion Criteria:

1. 'Red flag' items indicated in your Neck Medical Screening Questionnaire such as history of a tumor, bone fracture, metabolic diseases, Rheumatoid Arthritis, osteoporosis, severe atherosclerosis, prolonged history of steroid use, etc.
2. History of neck whiplash injury
3. Diagnosis from your physician of cervical spinal stenosis (narrowing of spinal canal) or presence of symptoms (pain, pins and needles, numbness) down both arms
4. Presence of central nervous system involvement such as exaggerated reflexes, changes in sensation in the hands, muscle wasting in the hands, impaired sensation of the face, altered taste, and presence of abnormal reflexes
5. Evidence of neurological signs consistent with nerve root entrapment (pinched nerve in the neck)
6. Prior surgery to your neck or upper back
7. A medical condition which may influence assessment of pain or pressure pain thresholds (i.e. taking analgesics, sedatives, history of substance abuse, or cognitive deficiency)
8. Diagnosis from your physician of fibromyalgia syndrome
9. Currently pregnant, or could be pregnant

Primary outcomes:
measure: Cervical Range of Motion
timeFrame: Immediately after the intervention
Secondary outcomes:
measure: Pain Pressure Threshold
timeFrame: Two minutes and 5 Minutes after the intervention
Other outcomes:
Locations:
city: Las Vegas
country: United States
facility: University of Nevada Las Vegas - Department of Physical Therapy
state: Nevada
Study officials:
affiliation: UNLV
name: Emilio J Puentedura, PT, DPT, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01590290: Randomized Controlled Cluster Trial of Resident Pay for Performance and Cardiovascular Outcomes
Official title: Randomized Controlled Cluster Trial of Resident Pay for Performance and Cardiovascular Outcomes
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Myocardial Infarction
Heart Failure
Lead sponsor: University of Virginia
Sponsor class: OTHER
First posted: 2012-05-02
Enrollment: 38
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if a pay for performance model in contrast to the traditional "fee for service" model may improve the number of patients discharged being treated in accordance with Joint Commission on Health Care JCAHO (a non-for profit organization that accredits health care organizations) standards and standard of care for management of hyperlipidemia

In this study the investigators will evaluate these two models by training resident physicians (doctors in training) on JCAHO core measures and specific criteria related to accepted standard of care for acute myocardial infarction and heart failure. The physicians will be randomized to a pay for performance or a fee for service model. Then a medical record review will be performed on patient records that received a discharge diagnosis of myocardial infarction or heart failure and were cared for by the physician subjects


Eligibility criteria: Inclusion Criteria:

* Physician inclusion: Resident physician on the Acute Cardiology Service, the Coronary Care Unit, or the General Medicine Service at the University of Virginia
* Patient inclusion: discharge diagnosis of heart failure or myocardial infarction.

Exclusion Criteria:

* Residents that are part of the study team

Primary outcomes:
measure: compliance with composite pay for performance measure
timeFrame: 1 month
Secondary outcomes:
measure: heart failure composite score
timeFrame: 1 month
measure: myocardial infarction score
timeFrame: 1 month
measure: readmission rate
timeFrame: 30 days
Other outcomes:
Locations:
city: Charlottesville
country: United States
facility: University of Virginia
state: Virginia
Study officials:
References:
Clinical trial NCT03743779: Mastering Diabetes Pilot Study
Official title: Mastering Diabetes Pilot Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes Mellitus
Keywords: diabetes
lifestyle
plant-based, whole food
vegetarian
vegan
exercise
Lead sponsor: Ohio University
Sponsor class: OTHER
First posted: 2018-11-16
Enrollment: 253
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: People with diabetes who enroll in the Mastering Diabetes program

Brief summary: This is a pilot study looking at past results of the Mastering Diabetes program utilizing a survey.

Detailed description: Adult past and present participants of Mastering Diabetes will be sent an email asking for their participation in the survey. The email will contain a hot link to a REDCap survey which will begin with a description of the study followed by a consent form. Once the consent is agreed, the survey will ask for participants' demographics and information about the variables described below

No personal identifiable information is being collected.

The data from this study will help develop a prospective study to better evaluate the effectiveness of Mastering Diabetes in controlling diabetes.

Future comparative studies between programs are anticipated, which will help identify the strengths and weaknesses of different programs, as well as identify subpopulations that might benefit from one program as opposed to another.

Data will be shared via posters and papers among the lifestyle medicine community to help contribute to better lifestyle interventions.

Eligibility criteria: Inclusion Criteria:

* Adult past and present participants of Mastering Diabetes

Exclusion Criteria:

* None

Primary outcomes:
measure: glycosylated hemoglobin
timeFrame: 1 year
measure: weight
timeFrame: 1 year
Secondary outcomes:
measure: perception of health change
timeFrame: 1 year
measure: perception of benefit
timeFrame: 1 year
measure: adherence
timeFrame: 1 year
Other outcomes:
Locations:
city: Athens
country: United States
facility: Ohio University
state: Ohio
Study officials:
affiliation: Ohio University
name: David Drozek, DO
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03460379: Bariatric Surgery and Pharmacokinetics of Escitalopram
Official title: Bariatric Surgery and Pharmacokinetics Escitalopram: BAR-MEDS Escitalopram
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Obesity, Morbid
Keywords: Bariatric surgery
Gastrointestinal tract
Biological availability
Pharmacokinetics
Citalopram
Lead sponsor: Norwegian University of Science and Technology
Sponsor class: OTHER
Collaborators: name: St. Olavs Hospital
name: Volvat Medisinsk Senter Stokkan
name: Namsos Hospital
name: Alesund Hospital
First posted: 2018-03-09
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients referred for bariatric surgery (gastric bypass or sleeve gastrectomy)

Brief summary: Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on escitalopram are investigated.


Eligibility criteria: Inclusion Criteria:

* Preparing to undergo gastric bypass or sleeve gastrectomy in Central Norway
* Being a Norwegian citizen

Exclusion Criteria:

* Having previously undergone resections in the GI-tract

Primary outcomes:
measure: Escitalopram concentration in blood serum (area under curve (AUC))
timeFrame: From baseline to 1 year postoperatively
Secondary outcomes:
Other outcomes:
Locations:
city: Trondheim
country: Norway
facility: St. Olavs University Hospital
Study officials:
affiliation: St. Olavs University Hospital
name: Magnus Strømmen, MSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04012879: Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic Leukemia
Official title: Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic Leukemia
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Relapsed Acute Lymphoblastic Leukemia
Refractory Acute Lymphoblastic Leukemia
Lead sponsor: Chinese PLA General Hospital
Sponsor class: OTHER
Collaborators: name: Shenzhen University General Hospital
First posted: 2019-07-09
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is a single-arm, open label, phase I clinical trial to evaluate the safety and feasibility of CD19CAR-T in treatment of relapsed / refractory acute lymphoblasic leukemia.


Eligibility criteria: Inclusion Criteria:

1. Diagnosis with Relapsed or refractory acute lymphocyte leukemia with CD19 positive
2. Age 18 to 65 years old, both male and female;
3. Is expected to survive more than 12 weeks;
4. Physical condition is good: 0-1 score ECOG score;
5. No obvious abnormal heart, liver, kidney, no large wounds that haven't healed on the body;
6. Into groups to participate in voluntarily, good adherence, can cooperate test observation, childbearing age women must be 7 days before starting treatment expert pregnancy test and the results were negative, and signed a written informed consent form.

Exclusion Criteria:

1. Organ failure, such as heart: Class III and IV; liver: to Child grading of liver function grade C; kidney: kidney failure and uremia stage; lung: symptoms of severe respiratory failure; brain: disorder of consciousness;
2. Existing serious acute infection, uncontrollable, or have fester sex and chronic infection, wound in delay no more;
3. Pregnancy and lactation women;
4. Patients who have participated in other clinical trials or other clinical trials in the past 30 days;
5. The Investigator believe the patients should not participate in this experiment.

Primary outcomes:
measure: recovery rate of patients being treated with CD19CAR-T
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Shenzhen
country: China
facility: Shenzhen University General Hospital
Study officials:
References:
Clinical trial NCT04319679: ESWT for UE Pain in Patients With Cervical Spinal Cord Injury
Official title: The Effects of Extracorporeal Shockwave Therapy (ESWT) for Upper Extremity Pain Related to Spasticity in Patients With Spinal Cord Injury
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Spastic Tetraplegia
Pain
Myelopathy Cervical
Keywords: Extracorporeal shockwave therapy
Cervical myelopathy
Spasticity
Pain
Lead sponsor: Bundang CHA Hospital
Sponsor class: OTHER
First posted: 2020-03-24
Enrollment: 4
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aimed to investigate the efficacy and safety of extracorporeal shockwave therapy (ESWT) for upper extremity pain related to spasticity in patients with spinal cord injury.

Detailed description: 6 times of ESWT (3,000 pulses per time, low energy under 0.3 mJ/m\^2, tolerable range) on forearm area to reduce pain related to spasticity in patients with cervical myelopathy

Eligibility criteria: Inclusion Criteria:

1. Spinal cord damage confirmed in the spinal cord image
2. 1 month after spinal cord injury
3. Spasticity of upper extremities
4. Pain in areas below spinal cord injury more than 4 points on the numerical scale (NRS)
5. Cognitive functions that can clearly point out NRS with more than 15 points in the mini mental state examination (MMSE)
6. Age: 20 and older
7. Person who has agreed in writing to decide his or her participation and comply with the precautions

Exclusion Criteria:

1. Pain due to trauma
2. Injection treatments two weeks before participating in the study
3. Severe coagulopathy (excluding antiplatelet use)
4. Impaired cognition

Primary outcomes:
measure: Numerical rating scale (NRS)
timeFrame: Up to 4 weeks (baseline, after each treatment during 2 weeks, 2 weeks + 1 day, 4 weeks)
Secondary outcomes:
measure: Modified Ashworth scale (MAS)
timeFrame: Up to 4 weeks (baseline, after each treatment during 2 weeks, 2 weeks + 1 day, 4 weeks)
measure: Range of motion (ROM)
timeFrame: Up to 4 weeks (baseline, 1 week, 2 weeks, 2 weeks + 1 day, 4 weeks)
measure: Grasp power
timeFrame: Up to 4 weeks (baseline, 2 weeks, 4 weeks)
Other outcomes:
Locations:
city: Seongnam
country: Korea, Republic of
facility: Department of Rehabilitation Medicine, CHA Bundang Medical Center,
Study officials:
affiliation: Department of Rehabilitation Medicine, CHA Bundang Medical Center, CHA University School of Medicine
name: Kyunghoon Min, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03730779: Oxygen Therapy for Retinal Ischemia
Official title: Normobaric Nocturnal Hyperoxia Therapy for Treating Ischemic-Related Retinal Conditions
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Retinal Ischemia
Lead sponsor: Beth Israel Deaconess Medical Center
Sponsor class: OTHER
First posted: 2018-11-05
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The investigators will be using nocturnal normobaric hyperoxia therapy in patients with diagnoses of conditions related to retinal ischemia.

Detailed description: Patients who receive a diagnosis of a condition relate to retinal ischemia and who pass the eligibility criteria will receive an oxygen concentrator to use at home. They will report back in follow up monthly for three to six months.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of retinal-ischemia related condition

Exclusion Criteria:

* Complicating other ocular condition
* History of smoking or lung conditions

Primary outcomes:
measure: Best Corrected Visual Acuity
timeFrame: 6 months
measure: Macula Edema
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Beth Israel Deaconess Medical Center
state: Massachusetts
Study officials:
References:
Clinical trial NCT00505479: Iodine Status in Pregnant Women and Their Newborns: is Congenital Hypothyroidism Related to Iodine Deficiency in Pregnancy?
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Congenital Hypothyroidism
Pregnancy
Iodine Deficiency
Keywords: Congenital Hypothyroidism
pregnancy
iodine
deficiency
Lead sponsor: Zhejiang University
Sponsor class: OTHER
First posted: 2007-07-23
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE

Brief summary: Iodine is an essential component of thyroid hormone, which is necessary for many metabolic processes as well as the maturation of the CNS. Deficiencies of iodine have deleterious effects on both pregnant women and infants. The iodine status of the population after implementation of the universal salt iodization program in Zhejiang province has not been known. This study was to determine whether pregnant women show evidence of iodine deficiency, and to examine the correlation between maternal urine iodine concentration and newborn thyroid function.

Detailed description: Iodine is an essential component of thyroid hormone, which is necessary for many metabolic processes as well as the maturation of the CNS. Deficiencies of iodine have deleterious effects on both pregnant women and infants. The iodine status of the population after implementation of the universal salt iodization program in Zhejiang province has not been known. This study was to determine whether pregnant women show evidence of iodine deficiency, and to examine the correlation between maternal urine iodine concentration and newborn thyroid function.

Healthy women at 12 weeks' gestation and over from four different areas in Zhejiang province were enrolled to participate this program from May 2007 to May 2010. Women consented to provide urine samples and salt samples during pregnancy (12, 16, 24 weeks' gestation and before delivery), and give permission to access their newborn's TSH value. Urinary iodine concentration (UIC) was determined by ammonium persulfate digestion microplate method, and TSH was determined by a time resolved fluoro-immunoassay (TRFIA). The diagnostic standard for congenital hypothyroidism was: TSH ≥ 20 mU/L and declined FT4 levels. Compare the correlation to effects with different level of iodine content in salt, maternal UIC and neonatal TSH. Investigate the optimal level of iodine content in salt in different areas in ZheJiang province.

Eligibility criteria: Inclusion Criteria:

* Pregnant women in Zhejiang province (and their newborns)

Exclusion Criteria:

* Endocrine disease

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: Children's Hospital Zhejiang University School of Medicine
state: Zhejiang
Study officials:
affiliation: Children's Hospital, Zhejiang University School of Medicine
name: zhengyan Zhao, M.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT04574479: Supra-inguinal Fascia Iliaca Compartment Block on Postoperative Management in Total Hip Arthroplasty by Posterior Approach
Official title: Impact of Supra-inguinal Fascia Iliaca Compartment Block on Postoperative Opioid Consumption in Total Hip Arthroplasty Interventions by Posterior Approach
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Arthropathy of Hip
Lead sponsor: University of Liege
Sponsor class: OTHER
First posted: 2020-10-05
Enrollment: 86
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Find the impact of supra-inguinal fascia iliaca compartment block on postoperative pain management after total hip arthroplasty by posterior surgical approach

Detailed description: ASA physical status 1, 2 and 3 patients scheduled to undergo elective surgery of total hip arthroplasty under spinal anesthesia.

The investigators would like to study the impact of supra-inguinal fascia iliaca block on postoperative pain management after total hip arthroplasty by posterior surgical approach. The principal investigator perform this block with ultrasound technique. The investigators also want to observe if this loco-regional new approach to fascia iliaca block could have influence on opioid side effects, postoperative nausea and vomiting, length of hospitalisation and first mobilisation side effects.

Eligibility criteria: Inclusion Criteria:

* Adults patients scheduled to undergo elective surgery of total hip arthroplasty by posterior surgical aboard

Exclusion Criteria:

* Patient refusal
* Allergy to used medications or local infection.
* Pregnancy
* Obesity with body mass index \> 35
* History of chronic pain or fibromyalgia
* Drug (opioids) addiction
* Treatment with corticosteroids for more than 6 months
* Severe kidney or liver diseases
* Mental disorders or serious neurological diseases

Primary outcomes:
measure: Opioid sparing
timeFrame: 48 hours after the intervention
Secondary outcomes:
measure: Opioid secondaries effects
timeFrame: 48 hours after the intervention
measure: Pain management satisfaction: questionnaire
timeFrame: 48 hours after the intervention
Other outcomes:
Locations:
city: Liège
country: Belgium
facility: CHU de Liège
Study officials:
References:
citation: Desmet M, Balocco AL, Van Belleghem V. Fascia iliaca compartment blocks: Different techniques and review of the literature. Best Pract Res Clin Anaesthesiol. 2019 Mar;33(1):57-66. doi: 10.1016/j.bpa.2019.03.004. Epub 2019 Apr 17.
citation: Carella M, Beck F, Piette N, Denys S, Kurth W, Lecoq JP, Bonhomme VL. Effect of suprainguinal fascia iliaca compartment block on postoperative opioid consumption and functional recovery in posterolateral-approached total hip arthroplasty: a single-blind randomized controlled trial. Reg Anesth Pain Med. 2022 Jun 15:rapm-2021-103427. doi: 10.1136/rapm-2021-103427. Online ahead of print.